#United States #Morristown #Whitehawk Therapeutics #oncology therapeutics #HWK-206

Whitehawk Therapeutics Reports First Quarter 2026 Financial Highlights

Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage company specializing in oncology therapeutics, has recently unveiled its financial results for the first quarter ending March 31, 2026. The updated report reflects the company's dedication to advancing its research initiatives and making significant contributions to cancer treatment. Dr. Dave Lennon, President and CEO of Whitehawk, emphasized the steady progress being made in their pipeline during this quarter.

Ongoing Clinical Trials

Whitehawk has been actively enrolling patients in Phase 1 dose-escalation studies for two of its critical therapeutic candidates, HWK-007 and HWK-016. HWK-007 is under evaluation for several types of cancer, including non-squamous EGFR wild-type non-small cell lung cancer, platinum-resistant ovarian cancer, and endometrial cancer (NCT07444814). Meanwhile, HWK-016 is being tested in patients with advanced ovarian and endometrial malignancies (NCT07470853). The completion of these studies is vital, with initial data from these trials expected in the first half of 2027.

Additionally, Whitehawk is preparing to submit an Investigational New Drug (IND) application for HWK-206, targeting small-cell lung cancer and neuroendocrine tumors, which is slated for mid-2026. Recruitment for the Phase 1 trial is planned to commence in the third quarter of 2026.

Financial Performance Overview

As of March 31, 2026, Whitehawk reported cash, cash equivalents, and short-term investments totaling $123.0 million, a decrease from $145.7 million at the end of 2025. However, this capital is sufficient to sustain operations into 2028, providing a stable foundation for ongoing research and development efforts. Research and development expenses for the quarter reached $17.2 million, highlighted by milestone costs associated with a license agreement with WuXi Biologics.

Despite these advances, Whitehawk reported a net loss of $22.2 million for Q1 2026, a significant change from the net income of $73.0 million reported for the same period last year. The previous year’s figures were bolstered by an $87.4 million gain from the sale of the Aadi Subsidiary, making this year's results a stark contrast.

Presentation of Key Data

In conjunction with its financial results, Whitehawk presented significant preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2026, which showcased the progress of its ADC (antibody-drug conjugate) portfolio. The data confirmed the efficacy of the next-generation ADC technology, supported by the proprietary Carbon Bridge Cysteine Re-pairing (CBCR) platform. The findings illustrated substantial tumor reductions, robust plasma stability, and favorable tolerability in non-human primate models, showcasing the potential of HWK-007 and HWK-016 while simultaneously displaying low systemic levels of free payload.

Moreover, analyses presented at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting provided insights regarding the MUC16 target, showing it as the most clinically relevant antigen with significantly higher expression in ovarian cancers compared to other targets. This highlights the strategic focus Whitehawk is placing on its ADC technology, aimed at creating impactful treatments in gynecological cancers.

Conclusion and Future Outlook

With a robust pipeline under development, Whitehawk Therapeutics remains committed to high-quality execution as it navigates through its research initiatives. The anticipation of initial results from the Phase 1 trials is fostering optimism that the company's innovative therapies could soon provide notable benefits for cancer patients. As they move forward, continuous monitoring of financial health and strategic planning will be crucial in maintaining momentum and advancing clinical research towards impactful therapeutic solutions.